Efficacy and Mechanism Evaluation (EME)
The Efficacy and Mechanism Evaluation Programme calls on the expertise, knowledge and opinion of a large number of people to ensure that the identification of research areas and funding decisions are chosen in a clear and fair way.
The EME Strategy Group advises the EME Programme Director on identification, development and prioritisation of research areas for advertisement through the commissioned workstream. In addition, it prioritises outline proposals received to the commissioned workstream for shortlisting by the EME Board.
The EME Board assesses outline and full proposals and makes funding decisions for the researcher-led workstream, and makes funding recommendations to the Department of Health for the commissioned workstream.
Members of EME advisory groups are required to declare any interests which conflict, or may be considered to conflict, with EME business, or may be perceived as influencing decisions made in the course of their work within the EME programme in line with the Conflicts of Interest Policy. All members are asked to complete the Register of Interest form (annually), which is intended to capture long term predictable interests that could be perceived to lead to conflicts of interest. These and other interests are judged on a case by case basis at individual meetings. View the Register of Interests for each EME programme advisory group.
Our Programme Director
Professor Tom Walley CBE, has been Programme Director of the EME Programme since its inception in 2008. He is also Director of NIHR Evaluation, Trials and Studies and Chair of the EME Strategy Group.
He is Professor of Clinical Pharmacology at Liverpool University and also works as a Consultant Physician at the Royal Liverpool University Hospital.
He formerly headed a research group at Liverpool University, focusing on drug prescribing, pharmaceutical policy, and clinical effectiveness and cost-effectiveness.
In June 2008, he was awarded a CBE by the Queen for his services to medicine.
The EME Board
|Professor David Crossman||Dean and Head of School of Medicine, University of St Andrews|
Professor David Crossman, is Bute Professor of Medicine and the Dean and Head of Faculty of Medicine at University of St. Andrews, Honorary Consultant Cardiologist for NHS Fife Health Board and Chief Scientist for Health, Scotland (from November 2017).
His previous appointments include Head of the School of Medicine at the Norwich Medical School, UEA, Director of the NIHR Cardiovascular Biomedical Research Centre and Professor of Clinical Cardiology at the University of Sheffield.
He has served on the EME Board (2010-2015) as well as the Wellcome Trust Expert Review Group – Physiology in Health and Disease (2010-2014), British Heart Foundation Chairs and Programme Grants Committee (2004-2009), MRC Physiological Systems and Clinical Sciences Board (2004-2008), as Vice President of Education and Research and Chair of Programme Committee for the British Cardiovascular Society (2006-2008). He was on the cardiovascular panel of RAE 2008 and Unit of assessment panel 1 in REF 2014.
His research interests centre on the inflammatory basis of atherosclerosis and the pathogenesis of myocardial infarction.
|Professor Eric Alton||Professor of Gene Therapy and Respiratory Medicine Imperial College London|
|Professor Tom Walley CBE||Director, EME Programme Department of Pharmacology & Therapeutics University of Liverpool|
|Dr Simon Bond||Senior Statistician from Cambridge Clinical Trials Unit, Addenbrooke’s Hospital Cambridge University Hospitals NHS Foundation Trust|
|Dr Louise Brown||Senior Statistician, MRC Clinical Trials Unit, University College London|
|Professor Bill Deakin||Professor of Psychiatry and Director NPU, Manchester University|
|Professor Anthony Dorling||Professor of Transplant Inflammation and Repair, MRC Centre for Transplantation, King’s College London|
|Dr Simon Drysdale||Clinical Lecturer and honorary specialty registrar in paediatric infectious diseases, University of Oxford and the Children’s Hospital, Oxford.|
|Professor Janet Dunn||Professor of Clinical Trials & Head of Cancer Trials, University of Warwick|
|Mr Stephen Edgar||Public board member|
|Professor Carrol Gamble||Reader Medical Statistics, University of Liverpool|
|Professor Paula Ghaneh||Professor of Surgery, University of Liverpool, Honorary Consultant Surgeon in Hepatobiliary Surgery, Royal Liverpool University Hospital|
|Professor Fiona Gilbert||Consultant Radiologist, Head of Department of Radiology at the University of Cambridge, Cambridge University Hospitals NHS Foundation Trust|
|Professor Ajit Lalvani||Director of Tuberculosis Research Centre, National Heart and Lung Institute, Imperial College London|
|Professor Iain McInnes||Professor of Experimental Medicine / Director of Research Institute, University of Glasgow|
|Mr Richard Parnell||Public board member|
|Dr Richard Peck||Head of Clinical Pharmacology, Roche Global; Roche Products Ltd.|
|Professor John Petrie||Professor of Diabetic Medicine, University of Glasgow|
|Professor Rustam Salman||Professor of Clinical Neurology & Honorary Consultant Neurologist, University of Edinburgh|
|Professor Robert Storey||Professor and Honorary Consultant in Cardiology, Medical School, University of Sheffield|
|Professor Frank Sullivan||Professor of Family and Community Medicine, University of St Andrews|
|Professor Steve Thornton||Vice Principal (Health) and Executive Dean, Queen Mary University of London|
|Professor Mark Thursz||Professor of Hepatology, Imperial College London and St Mary's Hospital London|
|Professor Christopher Weir||Professor of Medical Statistics and Clinical Trials, University of Edinburgh|
Our community of reviewers play a vital part in maintaining and improving the quality of the EME Programme projects and outputs. They are sought from a variety of fields, including from those who work in and use NHS services. To demonstrate our gratitude to our reviewers and acknowledge the important work they do for the programme the names of the past year’s reviewers are listed below.